Patents by Inventor Hong Moulton

Hong Moulton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Conjugate constructs, delivery, and use for treatment of disease
    Patent number: 8575126
    Abstract: Pharmaceutical formulations of antisense peptide-conjugated phosphorodiamidate morpholino olgomers and methods of use for treatment of apicomplexan infections are disclosed. The invention is particularly directed to treatment of Toxoplasma gondii infections.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: November 5, 2013
    Inventors: Rima McLeod, Bo Shiun Lai, William Witola, Kamal El Bissati, Ernest Mui, Hong Moulton, Jonathan B Rothbard, Jon D Moulton
  • Conjugate constructs, delivery, and use for treatment of disease
    Publication number: 20130053427
    Abstract: Pharmaceutical formulations of antisense peptide-conjugated phosphorodiamidate morpholino olgomers and methods of use for treatment of apicomplexan infections are disclosed. The invention is particularly directed to treatment of Toxoplasma gondii infections.
    Type: Application
    Filed: June 27, 2012
    Publication date: February 28, 2013
    Inventors: Rima McLeod, Bo Shiun Lai, William Witola, Kamal El Bissati, Ernest Mui, Hong Moulton, Jonathan B. Rothbard, Jon D. Moulton
  • Antisense compound and method for selectively killing activated T cells
    Publication number: 20050203041
    Abstract: A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions.
    Type: Application
    Filed: September 22, 2004
    Publication date: September 15, 2005
    Inventors: Dan Mourich, Hong Moulton, David Hinrichs, Patrick Iversen